Summit Therapeutics Jumps on $2 Billion AstraZeneca Investment
Summit Therapeutics Inc. shares rose after it said AstraZeneca Plc would make a $2 billion strategic equity investment in the cancer drugmaker to jointly develop drugs.
This is a short extract from a report by Bloomberg. The full text stays with the publisher — follow the link to read it there.
Read at source